JAMP-ALPRAZOLAM TABLET
Země: Kanada
Jazyk: angličtina
Zdroj: Health Canada
Charakteristika produktu
(SPC)
24-07-2018
Některé dokumenty pro tento produkt momentálně nejsou k dispozici, můžete poslat požadavek našemu zákaznickému servisu a my vás upozorníme, jakmile je dokážeme získat.
Poslat žádost.
Poslat žádost.
Aktivní složka:
ALPRAZOLAM
Dostupné s:
JAMP PHARMA CORPORATION
ATC kód:
N05BA12
INN (Mezinárodní Name):
ALPRAZOLAM
Dávkování:
0.25MG
Léková forma:
TABLET
Složení:
ALPRAZOLAM 0.25MG
Podání:
ORAL
Jednotky v balení:
100/500
Druh předpisu:
Targeted (CDSA IV)
Terapeutické oblasti:
BENZODIAZEPINES
Přehled produktů:
Active ingredient group (AIG) number: 0115008001; AHFS:
Stav Autorizace:
CANCELLED POST MARKET
Datum autorizace:
2020-04-01
Charakteristika produktu
Page 1 of 37
PRODUCT MONOGRAPH
JAMP-ALPRAZOLAM
0.25 MG, 0.5 MG, 1 MG AND 2 MG
ALPRAZOLAM TABLETS, USP
ANXIOLYTIC – ANTIPANIC
JAMP Pharma Corporation
Date of Revision: July 24, 2018
1310 rue Nobel
Boucherville, Québec
J4B 5H3
CONTROL# 217423
Page 2 of 37
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
................................................... 3
SUMMARY PRODUCT INFORMATION
.......................................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................................
3
CONTRAINDICATIONS
...................................................................................................................
5
WARNINGS AND PRECAUTIONS
.................................................................................................
5
ADVERSE REACTIONS
.................................................................................................................
12
DRUG INTERACTIONS
..................................................................................................................
16
DOSAGE AND ADMINISTRATION
...........................................................................................
19
OVERDOSAGE
................................................................................................................................
20
ACTION AND CLINICAL PHARMACOLOGY
...........................................................................
21
STORAGE AND STABILITY
.......................................................................................................
22
DOSAGE FORMS, COMPOSITION AND PACKAGING
.......................................................... 22
PART II: SCIENTIFIC INFORMATION
..........................................................................
24
PHARMACEUTICAL INFORMATION
........................................................................................
24
CLINICAL TRIALS
....................................................
Přečtěte si celý dokument
